Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Anlotinib Combined With Epirubicin for T4 Stage Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

NCT07616141 is registered in ClinicalTrials.gov with Eye & ENT Hospital of Fudan University as lead sponsor.

NCT NCT07616141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Anlotinib Combined With Epirubicin for T4 Stage Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Lead sponsor
Eye & ENT Hospital of Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 1, 2031
Enrollment
76 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma